JDRF and ViaCyte to move encapsulated cell therapy into clinical development for TI’s

home-banner-new-11

ViaCyte’s VC-01 product candidate is a cell replacement therapy that could transform the way individuals with type 1 diabetes manage their disease by supplying an alternative source of insulin-producing cells with the potential to free individuals from a dependence on external insulin use.

Read more

Posted in Artificial Pancreas Medical Research Type I